| II-56 Ricardo Nalda-Molina Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease. Wednesday 15:10-16:40 |
| II-56 Ricardo Nalda-Molina Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease. Wednesday 15:10-16:40 |